Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRA · 1 trial · 1 indication
AUC 0-24 of PRA when taken with SCY-078.
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | Single oral 20-mg dose of PRA on Day 1 AM |
| Treatment B | EXPERIMENTAL | Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later. |
| Name | Type | Description |
|---|---|---|
| PRA | DRUG | Single oral 20-mg dose of PRA on Day 1 AM |
| SCY-078 plus PRA | DRUG | Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later |
Inclusion Criteria: 1. is a male or female between 18 to 55 years, inclusive, of age at the prestudy (screening) visit (time of signing the Informed Consent). 2. has a Body Mass Index (BMI) 18.0 to 32 kg/m2 at the prestudy (screening) visit. 3. is judged to be in good health based on medical histor...
PRA is a small molecule drug being studied for pharmacokinetics, which is the measurement of how a drug is absorbed, distributed, metabolized, and excreted in the body. It is currently in Phase 1 clinical development as an investigational agent.
PRA is being developed by SCYNEXIS, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol SCYX. The company is conducting clinical research to evaluate the drug's pharmacokinetic properties.
PRA is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 study has been completed, and the drug is still in the early stages of clinical research.
PRA has one completed clinical trial registered under NCT04092751. This study evaluated the effect of SCY-078 (Ibrexafungerp) on the pharmacokinetics of Pravastatin in healthy subjects. The trial enrolled 28 participants in Australia and was a controlled, randomized study.
PRA is the abbreviation for pravastatin, a statin medication used to lower cholesterol. In the clinical trial NCT04092751, pravastatin was studied as a substrate to assess potential drug interactions with SCY-078 (Ibrexafungerp), an antifungal agent developed by SCYNEXIS.